Patient Guide: A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 6 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT07118241
Status: NOT_YET_RECRUITING
Condition: Sjögren's Syndrome
Phase: PHASE2

Where You Can Participate

This study is available at 6 locations across the country.

Top locations include:
  • • Sydney, New South Wales
  • • Sydney, New South Wales
  • • Brisbane, Queensland
  • • And 3 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE - Join Clinical Trial NCTNCT07118241

How to Join This Clinical Trial - NCTNCT07118241

Learn how to participate in this PHASE2 trial studying an investigational therapy for Sjögren's Syndrome. Current status: NOT_YET_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Sjögren's Syndrome. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Sjögren's Syndrome
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
NOT_YET_RECRUITING
Study Identifier
NCTNCT07118241 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 6 locations. Find a study site near you:

Clinical Research Site

Sydney, New South Wales - Australia

Status: Contact for availability

Clinical Research Site

Sydney, New South Wales - Australia

Status: Contact for availability

Clinical Research Site

Brisbane, Queensland - Australia

Status: Contact for availability

Clinical Research Site

Brisbane, Queensland - Australia

Status: Contact for availability

Clinical Research Site

Maroochydore, Queensland - Australia

Status: Contact for availability

Clinical Research Site

Melbourne, Victoria - Australia

Status: Contact for availability

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Sjögren's Syndrome:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships